Drug Interaction:
Antineoplastic agents include
Interferon ALFA 2a, Interferon ALFA -2b, Interferon ALFA -n3, Levamisole, Altretamine, Cladribine, Hydroxyurea, Aldesleukin, Paclitaxel, Docetaxel,Tretinion, Procarbazine,Dacarbazine, Gemcitabine, Mitotane, Asparaginase, Pegaspargase,Porfimer Sodium
Drug/Lab test interaction: Serum uric acid BUN and creatinine levels may be increased by hydroxyurea.
Indication:
Chronic myeloid leukemia, melanoma, recuurent ,metastatic or inoperable carcinoma of the ovary
Antineoplastic agents include-
Interferon ALFA 2a, Interferon ALFA -2b, Interferon ALFA -n3, Levamisole, Altretamine, Cladribine, Hydroxyurea, Aldesleukin, Paclitaxel, Docetaxel,Tretinion, Procarbazine,Dacarbazine, Gemcitabine, Mitotane, Asparaginase, Pegaspargase,Porfimer Sodium
Adverse Reaction:
Bone marrow depression,(leukopenia, anemia, and occassional thrombocytopenia) Stomatitis, anorexia, nausea, vomiting, diarrhea, and constipation.
Maculopapular rash, facial erythema. Alopecia,(rare). Headache, dizziness, disoreintation, hallucinations and convulsions. May temporarily impair renal tubular function
Contra-Indications:
Marked bone marrow depression, severe anemia
Dosages/ Overdosage Etc:
Chronic myeloid leukemia, melanoma, recuurent ,metastatic or inoperable carcinoma of the ovary
Dosage:
Intermittant therapy- 80mg/kg as a single dose every third day.
Continous therapy- 20 to 30mg/kg as a single daily dose.
Patient Information:
1. Notify physician if fever, chills, sore throat, nausea,vomiting, loss of appetite, diarhea, sores in the mouth, and on the lips, unusual bleeding or bruising occur
2. Medication may cause drowsiness, constipation, redness of the face, skin rash, itching, loss of hair. Notify if these become pronounced
3. Extra fluid intake is recommended.
4. Contrceptive measures are recommended during therapy
Pharmacology/ Pharmacokinetics:
Pharmacology:
Hydroxyurea cause an immediate inhibition of deoxyribonucleic acid(DNA) synthesis without interfering with the synthsis of ribonucleic acid(RNA) or protein
Pharmacokinetics:
Hydroxyurea is readily absorbed from the GI tract, reaching peak serum concentration within 2 hours., by 24 hours the serum concentration is zero. About 50% of the oral dose is degraded in the liver and excreted into the urine as urea and as respiratory carbon di oxide, the remainder is excreted in the urine
Pregnancy and lactation:
Pregnancy:
Do not use in women who are or who may become pregnant